Product information and disease descriptionPlace of product in therapyDisease description
Natural history, survival, and mortality
13 evidence topics · 12 sources
Estimated U.S. deaths in 2026 and death rate, all oral cavity and pharynx cancer
Estimated U.S. deaths in 2026 and death rate, all laryngeal cancer
| Measure | Quoted value |
|---|---|
| Estimated deaths in 2026 | “3,960” |
U.S. mortality trends, all oral cavity and pharynx cancer
Survival trend attributed to the changing share of smoking-related cancers, all oral cavity cancer
“For example, the increase in survival for people diagnosed with oral cavity cancers from 58% in the mid‐1990s to 69% in 2015–2021 partly reflects a decreased proportion of smoking‐related cancers and an increased proportion of HPV infection‐associated cancers, which typically have a better prognosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global deaths in 2024 by subsite, all histologies
| GLOBOCAN 2024 cancer site | Deaths | Percentage of all deaths |
|---|---|---|
| Lip, oral cavity | “194,108”View highlighted excerpt for this quote | “2.0”View highlighted excerpt for this quote |
| Larynx | “96,619”View highlighted excerpt for this quote | “1.0”View highlighted excerpt for this quote |
| Oropharynx | “51,823”View highlighted excerpt for this quote | “0.5”View highlighted excerpt for this quote |
| Hypopharynx | “49,748”View highlighted excerpt for this quote | “0.5”View highlighted excerpt for this quote |
HPV-negative versus HPV-positive survival, locally advanced oropharyngeal cancer treated with chemoradiotherapy
HPV-negative versus HPV-positive survival, population-based U.S. oropharyngeal cancer
“Median survival was significantly longer for HPV-positive than for HPV-negative patients (131 v 20 months; log-rank P < .001; adjusted hazard ratio, 0.31; 95% CI, 0.21 to 0.46). Survival significantly increased across calendar periods for HPV-positive (P = .003) but not for HPV-negative patients (P = .18).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Survival after recurrence of locoregionally advanced HNSCC in U.S. adults aged 66 years or older
“Within the resected cohort, patients with recurrence had a median OS of 23.8 months vs 44.4 months for patients without recurrence (P = 0.008); the 5-year OS rate was 30.2% compared with 42.5%, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, in the unresected cohort, the median OS was 23.7 months for patients with recurrence compared with 64.5 months for those without (P < 0.001), and the 5-year OS rate was 30.6% compared with 50.8%, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Median overall survival with first-line pembrolizumab regimens in recurrent or metastatic HNSCC at 4-year follow-up
“The median OS was 14.9 months (95% CI, 11.5 to 20.6) for pembrolizumab alone versus 10.8 months (95% CI, 8.8 to 12.8) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.61; 95% CI, 0.46 to 0.81; nominal one-sided P = .00034), 12.3 months (95% CI, 10.8 to 14.8) versus 10.4 months (95% CI, 9.0 to 11.7) in the CPS ≥ 1 population (HR, 0.74; 95% CI, 0.61 to 0.89; nominal one-sided P = .00080), and 11.5 months (95% CI, 10.3 to 13.5) versus 10.7 months (95% CI, 9.3 to 12.1) in the total population (HR, 0.81; 95% CI, 0.68 to 0.97; nominal one-sided P = .00994; Figs 2A-2C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median OS was 14.7 months (95% CI, 10.3 to 19.3) for pembrolizumab-chemotherapy versus 11.1 months (95% CI, 9.2 to 13.0) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.62; 95% CI, 0.46 to 0.84; nominal one-sided P = .00082), 13.6 months (95% CI, 10.7 to 15.5) versus 10.6 months (95% CI, 9.1 to 11.7) in the CPS ≥ 1 population (HR, 0.64; 95% CI, 0.53 to 0.78; nominal one-sided P = .00001), and 13.0 months (95% CI, 10.9 to 14.7) versus 10.7 months (95% CI, 9.3 to 11.7) in the total population (HR, 0.71; 95% CI, 0.59 to 0.85; nominal one-sided P = .00008; Figs 2D-2F).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Five-year overall survival with first-line pembrolizumab regimens in recurrent or metastatic HNSCC
Real-world overall survival with first-line pembrolizumab by HPV status in recurrent or metastatic HNSCC
“Among those receiving pembrolizumab monotherapy, the median rwOS was 20 months for those with HPV-positive tumors versus 9 months for those with HPV-negative tumors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among individuals receiving pembrolizumab plus chemotherapy, the median rwOS was 15 months for those with HPV-positive tumors versus 7 months for those with HPV-negative tumors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote